Navigation Links
Selecting siRNA Sequences to Incorporate into the pSilencer Vectors


The first step in preparing a plasmid for siRNA experiments is to identify target sequences in the gene of interest that are susceptible to siRNA-induced degradation. We have found that a little more than half of the siRNAs provide at least a 50% reduction in target mRNA levels and approximately 1 out of 4 siRNAs provide a 75-95% reduction. The general process begins with scanning the length of the target gene for potential siRNA target sites. For siRNA expression vectors, the target sites should have 5' terminal AAs because, upon folding the siRNAs hairpins will give rise to UU overhangs. These UU overhangs will therefore be complementary to the AA in the target site. The 21 nucleotide siRNA target sequences are then compared to an appropriate genome database to eliminate sequences with significant homology to other genes. For screening, we typically test four siRNAs per target. We space the siRNAs down the length of the gene sequence to reduce the chances of targeting a region of the mRNA that is either highly structured or bound by regulatory proteins.

Constructing four siRNA expression plasmids for each target can be time-consuming and expensive. In vitro transcription provides a less formidable siRNA screening method. To ensure that siRNAs expressed from plasmids are functionally equivalent to siRNAs prepared by in vitro transcription, we prepared plasmids and siRNAs targeting four different sequences in the cyclophilin and GAPDH genes. These nucleic acids were transfected into HeLa cells. Silencing was evaluated by Northern analysis using probes specific to GAPDH, cyclophilin, and 28S rRNA. The hybridiz ation signal from the various targets was quantitated by phosphorimager. As seen in Figure 1, the susceptibility of siRNA target sites to siRNA-mediated gene silencing appears to be comparable for both in vitro prepared siRNAs and RNA Pol III-expressed siRNAs. This is also true for chemically synthesized siRNAs versus RNA Pol III-expressed siRNAs. Therefore, it is not necessary to re-screen genes for which functional siRNAs have already been identified.

Transcribed siRNA siRNAVector GAPDH None 100% 100% 5' 25% 17% 5' Medial 7% 13% 3' Medial 36% 20% 3' 45% 63% Cyclophilin None 100% 100% 5' 5% 23% 5' Medial 15% 19% 3' Medial 45% 29% 3' 70% 54%

Figure 1. Correlation of Target Site Selection Between siRNA Generated In Vitro and In Vivo. siRNAs to four target sites in each of two genes (GAPDH and cyclophilin) were selected and prepared using the Silencer siRNA Construction Kit. Sequences encoding hairpin siRNAs to the same target sequences were sub-cloned into pSilencer 2.0-U6 and 3.0-H1. The siRNAs and siRNA expression vectors were transfected into HeLa cells using siPORT-Lipid (Ambion). Target RNA levels were assessed post-transfection (48 hr) by Northern analysis using the NorthernMax procedure (Ambion). The relative levels of the target genes were measured against cells transfected with negative control siRNA or negative control siRNA expression vector.


back to top


Ordering Information
Cat# Product Name Size 1620 Silencer siRNA Construction Kit 15 siRNA synthesis rxns 7207 pSilencer 1.0-U6 (circular) 20 g 7208 pSilencer 1.0-U6 (linear) 20 rxns 7209 pSilencer 2.0-U6 20 rxns 7210 pSilencer 3.0-H1 20 rxns
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Custom and library siRNA for efficient gene silencing
2. Custom and library siRNA for efficient gene silencing
3. Cancer siRNA Oligo Set Version 1.0
4. Library siRNA
5. Custom siRNA Oligo Synthesis Service
6. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
7. Quantification of siRNA Silencing Efficiency Using the LightCycler System
8. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
9. Confirming gene silencing mechanism by pGFP/GFP22 siRNA co-transfection
10. siRNA transfection optimization with the Agilent 2100 bioanalyzer
11. siRNA Design Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... Feb. 8, 2016  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has ... with Hercules Technology Growth Capital, Inc. and Hercules ... in financing. --> ... million of financing under the loan and security ...
(Date:2/8/2016)... Novan, Inc. today announced that Director Robert A. Ingram ... In addition, Robert Keegan has been appointed to the ... --> North Carolina . ... of $32.8 million of net proceeds in a private Mezzanine B ... the Research Triangle area of North Carolina . ...
(Date:2/8/2016)... 2016  BioElectronics Corporation (OTC Pink: BIEL), the ... that it is responding to a notice of ... and Exchange Commission posted on the agency website.  ... the Board of BioElectronics Corporation and the Edward ... The Fuqua School of Business, Duke University.   ...
(Date:2/8/2016)... ... February 08, 2016 , ... Bulk food product ... foods at various stages of the production process. Despite frequently inspecting loose product ... products post packaging such as sacks of dry powders. , Mettler-Toledo Product Inspection's ...
Breaking Biology Technology:
(Date:2/3/2016)... Calif. , Feb. 3, 2016 Vigilant ... Police Department in Missouri ... license plate reader (LPR) data from Vigilant Solutions. ... hit-and-run case in which the victim was walking out of a convenience ... parking space next to his vehicle, striking his vehicle ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
Breaking Biology News(10 mins):